MedWorm: Lymphoma

Cancer in patients with motor neuron disease, multiple sclerosis and Parkinson's disease: record linkage studies

Journal of Neurology, Neurosurgery & Psychiatry — Tue, 09 Feb 2010 15:00:05 +0100

Conclusions People with MND, or MS, do not have an altered risk of cancer overall. There may sometimes be misdiagnosis between MND or MS and brain tumours. PD carries a reduced risk of cancer overall, of some smoking related cancers and of some cancers that are not smoking related. (Source: Journal of Neurology, Neurosurgery & Psychiatry)

MedWorm Sponsor Message: The Lymphoma Research Foundation (LRF) is America's largest lymphoma-focused voluntary health organization devoted exclusively to funding lymphoma research and providing patients and health care professionals with critical information on the disease.

Metabolite Common Among Cancers

Lymphoma / Leukemia News From Medical News Today — Tue, 09 Feb 2010 11:00:00 +0100

NICE Appraisal Of Dasatinib And Nilotinib For Chronic Myeloid Leukaemia

Lymphoma / Leukemia News From Medical News Today — Tue, 09 Feb 2010 11:00:00 +0100

Metabolite Common Among Cancers

Health News from Medical News Today — Tue, 09 Feb 2010 11:00:00 +0100

A study published online on February 8 in the Journal of Experimental Medicine reports that several distinct mutations found in a subset of patients with acute myelogenous leukemia (AML) result in excess production of the same metabolite. The enzyme isocitrate dehydrogenase 1 (IDH1), which normally facilitates production of the metabolite {alpha}-ketoglutarate, is mutated in approximately 80% of secondary brain tumors. This mutant version of IDH1 promotes excess production of a different metabolite: R (-)-2-hydroxyglutarate (2-HG)... (Source: Health News from Medical News Today)

NICE Appraisal Of Dasatinib And Nilotinib For Chronic Myeloid Leukaemia

Health News from Medical News Today — Tue, 09 Feb 2010 11:00:00 +0100

The National Institute for Health and Clinical Excellence (NICE) has updated its draft guidance on the use of dasatinib (Sprycel,made by Bristol Myers-Squibb) and nilotinib (Tasigna,made by Novartis) for chronic myeloid leukaemia. Following the previous public consultation and subsequent independent Appraisal Committee meeting on 13 January 2010, both NICE and the appraisal committee agreed to split the appraisal of dasatinib and nilotinib for chronic myeloid leukaemia into two separate appraisals. To effectively appraise a new treatment, the Committee compares it to an existing one... (Source: Health News from Medical News Today)

EBV-positive Hodgkin lymphoma is associated with suppression of p21cip1/waf1 and a worse prognosis

Molecular Cancer — Tue, 09 Feb 2010 00:00:00 +0100

Conclusion: Although the underlying mechanisms are unclear, EBER1 inhibits p21cip1/waf1 transcription and prevents apoptosis through down-regulation of p53, EGR1, and STAT1. The anti-apoptotic activity of EBER1 may be important in the rescue of Reed-Sternberg cells from drug-induced apoptosis and in the clinical behaviors of EBV+ HLs. (Source: Molecular Cancer)

Incidence and prognostic impact of secondary cytogenetic aberrations in a series of 145 patients with mantle cell lymphoma

Genes, Chromosomes and Cancer — Tue, 09 Feb 2010 00:00:00 +0100

Mantle cell lymphoma (MCL) is a mature B-cell neoplasm with an aggressive behavior, characterized by the t(11;14)(q13;q32). Several secondary genetic abnormalities with a potential role in the oncogenic process have been described. Studies of large MCL series using conventional cytogenetics, and correlating with proliferation and survival, are scarce. We selected 145 MCL cases at diagnosis, displaying an aberrant karyotype, from centers belonging to the Spanish Cooperative Group for Hematological Cytogenetics. Histological subtype, proliferative index and survival data were ascertained. Combined cytogenetic and molecular analyses detected CCND1 translocations in all cases, mostly t(11;14)(q13;q32). Secondary aberrations were present in 58% of patients, the most frequent being deletions of ...

Chromosome 8p11.2 translocations: Prevalence, FISH analysis for FGFR1 and MYST3, and clinicopathologic correlates in a consecutive cohort of 13 cases from a single institution

American Journal of Hematology — Tue, 09 Feb 2010 00:00:00 +0100

Chromosome 8p11.2 translocations result in diverse oncogenic fusion genes involving FGFR1 or MYST3. Among 24,262 unique patient cytogenetic studies performed at the Mayo Clinic, 8p11.2 translocations were identified in 14 cases ([sim]0.06%). FISH analysis was performed in 13 patients (12 had myeloid neoplasms) and revealed abnormalities of MYST3 (n = 4) or FGFR1 (n = 4) in eight patients. MYST3 abnormalities were associated with acute myeloid leukemia (AML), M4 in three and M6 in one. Three of the four FGFR1-rearranged cases were associated with myeloproliferative neoplasms but none, including the two with sole 8p11.2, displayed the typical phenotype for stem cell leukemia/lymphoma (SCLL) and only one had eosinophilia; the fourth case had AML-M4. FISH did not reveal FGFR1 involvement in th...

Epstein-Barr Virus-Positive Diffuse Large B-Cell Lymphoma During Therapy With Alemtuzumab for T-Cell Prolymphocytic Leukemia [DIAGNOSIS IN ONCOLOGY]